Humacyte Announces Third Quarter Results: Symbios Revenue Growth and Clinical Progress
HUMA Humacyte Inc
$0.59 +29.61%
View chart & analysis → - 1Humacyte, Inc. recorded a 151% increase in Symbios revenue for the third quarter.
- 2The number of hospitals ordering Humacyte's Symbios increased by 44%, rising from 34 at the end of the second quarter to 49 as of September 30.
- 3Humacyte has commenced its first human clinical phase 2a study this month for coronary artery tissue-engineered vessels for coronary artery bypass grafting.
So what's the key point?
Humacyte's Symbios revenue grew significantly by 151%. The number of hospitals ordering the product is also increasing, and a new human clinical study has begun.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.